NeuroScientific Biopharmaceuticals Limited

ASX:NSB Stock Report

Market Cap: AU$6.5m

NeuroScientific Biopharmaceuticals Past Earnings Performance

Past criteria checks 3/6

NeuroScientific Biopharmaceuticals's earnings have been declining at an average annual rate of -13.6%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 74.9% per year. NeuroScientific Biopharmaceuticals's return on equity is 20%, and it has net margins of 20.1%.

Key information

-13.6%

Earnings growth rate

2.7%

EPS growth rate

Biotechs Industry Growth9.6%
Revenue growth rate74.9%
Return on equity20.0%
Net Margin20.1%
Last Earnings Update31 Dec 2023

Recent past performance updates

No updates

Recent updates

Is NeuroScientific Biopharmaceuticals (ASX:NSB) In A Good Position To Deliver On Growth Plans?

May 25
Is NeuroScientific Biopharmaceuticals (ASX:NSB) In A Good Position To Deliver On Growth Plans?

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

Jan 27
Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

NeuroScientific Biopharmaceuticals (ASX:NSB) Is In A Good Position To Deliver On Growth Plans

Oct 07
NeuroScientific Biopharmaceuticals (ASX:NSB) Is In A Good Position To Deliver On Growth Plans

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Can Afford To Invest In Growth

Jun 23
Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Can Afford To Invest In Growth

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

Mar 10
Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

We're Hopeful That NeuroScientific Biopharmaceuticals (ASX:NSB) Will Use Its Cash Wisely

Nov 18
We're Hopeful That NeuroScientific Biopharmaceuticals (ASX:NSB) Will Use Its Cash Wisely

Revenue & Expenses Breakdown
Beta

How NeuroScientific Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:NSB Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 234121
30 Sep 234023
30 Jun 235-124
31 Mar 233-425
31 Dec 221-836
30 Sep 221-937
30 Jun 220-1037
31 Mar 220-936
31 Dec 211-835
30 Sep 211-524
30 Jun 211-322
31 Mar 210-322
31 Dec 200-211
30 Sep 200-311
30 Jun 200-311
31 Mar 200-311
31 Dec 190-311
30 Sep 190-211
30 Jun 190-211
31 Mar 190-211
31 Dec 180-110
30 Sep 180-110
30 Jun 180-110
31 Mar 180-100
31 Dec 170000
30 Sep 170000
30 Jun 170000
30 Jun 160000

Quality Earnings: NSB has high quality earnings.

Growing Profit Margin: NSB became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NSB has become profitable over the past 5 years, growing earnings by -13.6% per year.

Accelerating Growth: NSB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: NSB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.3%).


Return on Equity

High ROE: NSB's Return on Equity (20%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.